Trimidox
(Synonyms: VF 233) 目录号 : GC13399
A ribonucleotide reductase inhibitor
Cas No.:95933-74-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Trimidox (3.4.5-tri-hydroxybenzohydroxamidoxime) is a specific and patented ribonucleotide reductase (RNR) inhibitor [1].
Ribonucleotide reductase (RNR), also known as ribonucleoside diphosphate reductase, is an enzyme involved in catalyzing the formation of deoxyribonucleotides from ribonucleotides. RNR plays a vital role in regulating the total rate of DNA synthesis to DNA to maintain DNA cell mass a constant ratio during cell division and DNA repair. The substrates for RNR are ADP, GDP, CDP and UDP [2]. Increased ribonucleotide reductase (RNR) activity has been associated with malignant transformation and tumor cell growth [1].
In human promyelocytic leukemia HL-60 cells, trimidox inhibited the growth of with an IC50 of 35 pmol/L. Treatment with trimidox (50 pmol/L) for 24 hours decreased deoxyguanosine triphosphate (dGTP) and deoxycytidine triphosphate (dCTP) pools to 24% and 3946 of control values, respectively. Incubation of HL-60 cells with 20 to 80 pmol/L trimidox to 4 days showed no effects in the distribution of cells indifferent phases of cell cycle [1]. Trimidox in combination with tiazofurin was useful in the treatment of leukemia [1].
References:
[1] Szekeres T, Fritzer M, Strobl H, et al. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells[J]. Blood, 1994, 84(12): 4316-4321.
[2] Elledge S J, Zhou Z, Allen J B. Ribonucleotide reductase: regulation, regulation, regulation[J]. Trends in biochemical sciences, 1992, 17(3): 119-123.
| Cas No. | 95933-74-7 | SDF | |
| 别名 | VF 233 | ||
| 化学名 | N,3,4,5-tetrahydroxy-benzenecarboximidamide | ||
| Canonical SMILES | OC1=C(O)C(O)=CC(C(NO)=N)=C1 | ||
| 分子式 | C7H8N2O4 | 分子量 | 184.2 |
| 溶解度 | ≤20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.4289 mL | 27.1444 mL | 54.2888 mL |
| 5 mM | 1.0858 mL | 5.4289 mL | 10.8578 mL |
| 10 mM | 0.5429 mL | 2.7144 mL | 5.4289 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet